These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 33688003)
1. Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. Bartsch YC; Loos C; Rossignol E; Fajnzylber JM; Yuan D; Avihingsanon A; Ubolyam S; Jupimai T; Hirschel B; Ananworanich J; Lauffenburger DA; Li JZ; Alter G; Julg B mBio; 2021 Mar; 12(2):. PubMed ID: 33688003 [TBL] [Abstract][Full Text] [Related]
2. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. Li JZ; Heisey A; Ahmed H; Wang H; Zheng L; Carrington M; Wrin T; Schooley RT; Lederman MM; Kuritzkes DR; AIDS; 2014 Nov; 28(18):2649-57. PubMed ID: 25254301 [TBL] [Abstract][Full Text] [Related]
3. Establishment of a Novel Humanized Mouse Model To Investigate Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677 [TBL] [Abstract][Full Text] [Related]
4. Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells. Hendricks CM; Cash MN; Tagliamonte MS; Riva A; Brander C; Llano A; Salemi M; Stevenson M; Mavian C Microbiol Spectr; 2022 Aug; 10(4):e0135322. PubMed ID: 35699458 [TBL] [Abstract][Full Text] [Related]
5. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444 [TBL] [Abstract][Full Text] [Related]
6. Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. Giron LB; Papasavvas E; Azzoni L; Yin X; Anzurez A; Damra M; Mounzer K; Kostman JR; Sanne I; Firnhaber CS; Tateno H; Liu Q; Montaner LJ; Abdel-Mohsen M AIDS; 2020 Apr; 34(5):681-686. PubMed ID: 31972605 [TBL] [Abstract][Full Text] [Related]
7. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. Chun TW; Justement JS; Murray D; Hallahan CW; Maenza J; Collier AC; Sheth PM; Kaul R; Ostrowski M; Moir S; Kovacs C; Fauci AS AIDS; 2010 Nov; 24(18):2803-8. PubMed ID: 20962613 [TBL] [Abstract][Full Text] [Related]
8. Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy. Scherpenisse M; Kootstra NA; Bakker M; Berkhout B; Pasternak AO mBio; 2021 Mar; 12(2):. PubMed ID: 33688002 [TBL] [Abstract][Full Text] [Related]
9. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment. Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299 [TBL] [Abstract][Full Text] [Related]
10. Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption. Ziani W; Shao J; Wang X; Russell-Lodrigue K; Liu YZ; Montaner LJ; Veazey RS; Xu H J Virol; 2021 Feb; 95(6):. PubMed ID: 33408173 [TBL] [Abstract][Full Text] [Related]
17. Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. Vibholm LK; Konrad CV; Schleimann MH; Frattari G; Winckelmann A; Klastrup V; Jensen NM; Jensen SS; Schmidt M; Wittig B; Zuwala K; Mack K; Olesen R; Hua S; Lichterfeld M; Østergaard L; Denton PW; Tolstrup M; Søgaard OS AIDS; 2019 Jul; 33(8):1315-1325. PubMed ID: 30932955 [TBL] [Abstract][Full Text] [Related]
18. Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity. Chung AW; Mabuka JM; Ndlovu B; Licht A; Robinson H; Ramlakhan Y; Ghebremichael M; Reddy T; Goulder PJR; Walker BD; Ndung'u T; Alter G AIDS; 2018 Jun; 32(10):1207-1217. PubMed ID: 29620716 [TBL] [Abstract][Full Text] [Related]
19. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595 [TBL] [Abstract][Full Text] [Related]
20. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. Li JZ; Etemad B; Ahmed H; Aga E; Bosch RJ; Mellors JW; Kuritzkes DR; Lederman MM; Para M; Gandhi RT AIDS; 2016 Jan; 30(3):343-53. PubMed ID: 26588174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]